These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 15001459)
1. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Schmitt M; Gunaruwan P; Payne N; Taylor J; Lee L; Broadley AJ; Nightingale AK; Cockcroft JR; Struthers AD; Tyberg JV; Frenneaux MP Arterioscler Thromb Vasc Biol; 2004 May; 24(5):911-7. PubMed ID: 15001459 [TBL] [Abstract][Full Text] [Related]
2. Atrial natriuretic peptide regulates regional vascular volume and venous tone in humans. Schmitt M; Broadley AJ; Nightingale AK; Payne N; Gunaruwan P; Taylor J; Lee L; Cockcroft J; Struthers AD; Frenneaux MP Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1833-8. PubMed ID: 12842844 [TBL] [Abstract][Full Text] [Related]
3. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247 [TBL] [Abstract][Full Text] [Related]
4. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Nakamura M; Arakawa N; Yoshida H; Makita S; Hiramori K Circulation; 1994 Sep; 90(3):1210-4. PubMed ID: 8087930 [TBL] [Abstract][Full Text] [Related]
5. Endothelial NO/cGMP system contributes to natriuretic peptide-mediated coronary and peripheral vasodilation. Brunner F; Wölkart G Microvasc Res; 2001 Jan; 61(1):102-10. PubMed ID: 11162200 [TBL] [Abstract][Full Text] [Related]
6. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Nakamura M; Arakawa N; Yoshida H; Makita S; Niinuma H; Hiramori K Am Heart J; 1998 Mar; 135(3):414-20. PubMed ID: 9506326 [TBL] [Abstract][Full Text] [Related]
7. Vascular effects of natriuretic peptides in healthy men. Komarek M; Bernheim A; Schindler R; Steden R; Kiowski W; Brunner-La Rocca HP J Cardiovasc Pharmacol Ther; 2004 Dec; 9(4):263-70. PubMed ID: 15678245 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of relaxation and cGMP production in human coronary by-pass grafts in response to stimulation with natriuretic peptides and a nitric oxide donor. Hammerer-Lercher A; Fersterer J; Holzmann S; Bonatti J; Ruttmann E; Hoefer D; Mair J; Puschendorf B Clin Sci (Lond); 2006 Sep; 111(3):225-31. PubMed ID: 16709152 [TBL] [Abstract][Full Text] [Related]
9. An inhibitor of inducible nitric oxide synthase decreases forearm blood flow in patients with congestive heart failure. Ishibashi Y; Shimada T; Murakami Y; Takahashi N; Sakane T; Sugamori T; Ohata S; Inoue S; Ohta Y; Nakamura K; Shimizu H; Katoh H; Hashimoto M J Am Coll Cardiol; 2001 Nov; 38(5):1470-6. PubMed ID: 11691525 [TBL] [Abstract][Full Text] [Related]
10. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. Springer J; Azer J; Hua R; Robbins C; Adamczyk A; McBoyle S; Bissell MB; Rose RA J Mol Cell Cardiol; 2012 May; 52(5):1122-34. PubMed ID: 22326431 [TBL] [Abstract][Full Text] [Related]